Literature DB >> 12072687

Vasopressin improves survival in a pig model of hypothermic cardiopulmonary resuscitation.

Birgit Schwarz1, Peter Mair, Claus Raedler, Diana Deckert, Volker Wenzel, Karl H Lindner.   

Abstract

OBJECTIVE: During hypothermic cardiopulmonary resuscitation with a body core temperature <30 degrees C administration of a vasopressor to support coronary perfusion pressure is controversial. The purpose of the current study was to assess the effects of a single 0.4-unit/kg dose of vasopressin on coronary perfusion pressure, defibrillation success, and 1-hr survival in a pig model of hypothermic closed-chest cardiopulmonary resuscitation combined with rewarming.
DESIGN: Prospective, randomized study in an established pig model.
SETTING: University hospital research laboratory.
SUBJECTS: Fifteen 12- to 16-wk-old domestic pigs.
INTERVENTIONS: Pigs were surface cooled to a body core temperature of 26 degrees C and ventricular fibrillation was induced. After 15 mins of untreated cardiac arrest, manual closed-chest cardiopulmonary resuscitation and thoracic lavage with 40 degrees C warmed tap water were started. After 3 mins of external chest compression, animals were assigned randomly to receive vasopressin (0.4 units/kg, n = 8; or saline placebo, n = 7). Defibrillation was attempted 10 mins after drug administration.
MEASUREMENTS AND MAIN RESULTS: Compared with saline placebo treated-animals, coronary perfusion pressure in vasopressin-treated pigs was significantly higher 90 secs (36 +/- 5 mm Hg vs. 7 +/- 4 mm Hg, p =.000) to 10 mins (24 +/- 4 mm Hg vs. 8 +/- 4 mm Hg, p =.000) after drug administration. Restoration of spontaneous circulation and 1 hr survival were significantly higher in vasopressin animals compared with saline placebo (8 of 8 vasopressin pigs vs. 0 of 7 placebo pigs, p <.001).
CONCLUSIONS: A single 0.4-unit/kg dose of vasopressin administered at a body core temperature <30 degrees C significantly improved defibrillation success and 1-hr survival in a pig model of hypothermic cardiopulmonary resuscitation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12072687     DOI: 10.1097/00003246-200206000-00027

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  6 in total

Review 1.  [Avalanche emergencies. Review of the current situation].

Authors:  P Paal; W Beikircher; H Brugger
Journal:  Anaesthesist       Date:  2006-03       Impact factor: 1.041

2.  Vasopressin treatment of verapamil toxicity in the porcine model.

Authors:  J Dave Barry; Dave Durkovich; Lee Cantrell; William Richardson; Tri Tong; Steve Offerman; Richard F Clark; David A Tanen; Saralyn Williams
Journal:  J Med Toxicol       Date:  2005-12

Review 3.  Drug administration in animal studies of cardiac arrest does not reflect human clinical experience.

Authors:  Joshua C Reynolds; Jon C Rittenberger; James J Menegazzi
Journal:  Resuscitation       Date:  2007-03-13       Impact factor: 5.262

Review 4.  Accidental hypothermia-an update : The content of this review is endorsed by the International Commission for Mountain Emergency Medicine (ICAR MEDCOM).

Authors:  Peter Paal; Les Gordon; Giacomo Strapazzon; Monika Brodmann Maeder; Gabriel Putzer; Beat Walpoth; Michael Wanscher; Doug Brown; Michael Holzer; Gregor Broessner; Hermann Brugger
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2016-09-15       Impact factor: 2.953

5.  Successful Pre-Rewarming Resuscitation after Cardiac Arrest in Severe Hypothermia: A Retrospective Cohort Study from the International Hypothermia Registry.

Authors:  Evelien Cools; Marie Meyer; Delphine Courvoisier; Beat Walpoth
Journal:  Int J Environ Res Public Health       Date:  2022-03-29       Impact factor: 3.390

6.  Study of the Effects of 3 h of Continuous Cardiopulmonary Resuscitation at 27°C on Global Oxygen Transport and Organ Blood Flow.

Authors:  Jan Harald Nilsen; Sergei Valkov; Rizwan Mohyuddin; Torstein Schanche; Timofei V Kondratiev; Torvind Naesheim; Gary C Sieck; Torkjel Tveita
Journal:  Front Physiol       Date:  2020-04-16       Impact factor: 4.566

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.